Dr Ash Wechalekar, Consultant Haematologist

Dr Ash Wechalekar

Consultant Haematologist

Book online
|

Dr Ash Wechalekar MB BS, MD, FRCP, FRCPath, DM

Consultant Haematologist

MB BS, MD, FRCP, FRCPath, DM

Dr Ash Wechalekar

Consultant Haematologist MB BS, MD, FRCP, FRCPath, DM

Book online
|
MB BS, MD, FRCP, FRCPath, DM

Areas of expertise

  • Multiple myeloma
  • Systemic amyloidosis
  • MGUS (monoclonal gammopathy of undetermined significance)
  • General haematology
  • Blood cancer

Address

  • HCA UK at University College Hospital

    Grafton Way Building, 1 Grafton Way, London, WC1E 6AG

About Dr Ash Wechalekar

GMC number: 5191273

Year qualified: 1992

Place of primary qualification: Nagpur University

Professor Ashutosh Wechalekar is an internationally renowned Consultant Haematologist who specialises in plasma cell disorders, with a focus on MGUS, multiple myeloma, monoclonal protein-related disorders (MGRS), and all types of amyloidosis.

He is part of the largest UK myeloma service at University College London Hospitals (UCLH) and leads Haematology at the National Amyloidosis Centre based at the Royal Free Hospital. Additionally, he is the lead for the AL amyloidosis treatment programme. Professor Wechalekar also serves as the Director of the laboratory at the National Amyloidosis Centre.

Professor Wechalekar is highly active in clinical research, developing a trials network in the UK for AL amyloidosis and acting as Principal Investigator or Chief Investigator on numerous myeloma clinical trials. His work is widely published both nationally and internationally in these areas.

Areas of expertise

  • Myeloma
  • Amylodoisis
  • Waldenstrom’s macroglobulinaemia
  • Plasma cell dyscrasia
  • Renal disease

Professional memberships

Royal College of Physicians
General Medical Council

Articles by Dr Ash Wechalekar

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of national amyloidosis centre transthyretin amyloidosis stage

Eight novel loci implicate shared genetic etiology in multiple myeloma, al amyloidosis, and monoclonal gammopathy of unknown significance

Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in al amyloidosis

Preclinical toxicology and safety pharmacology of the first-in-class gadd45β/mkk7 inhibitor and clinical candidate, dtp3

Outcomes of 44 patients with newly diagnosed systemic light-chain amyloidosis associated with deletion 17p

Extracardiac 18f-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds

The amyloidosis forum: a public private partnership to advance drug development in al amyloidosis

Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis

Deferred autologous stem cell transplantation in systemic al amyloidosis